Background
==========

Crohn's disease (CD) is a major component of chronic idiopathic inflammatory disease, which primarily affects the terminal ileum and colon. A prospective, population-based study showed that the incidence rate for CD was as high as 1.09 per 100 000 person-years in China \[[@b1-medscimonit-25-9637]\]. Although the CD prevalence in China is still lower than that in Western countries, this figure has increased rapidly over the past few decades \[[@b2-medscimonit-25-9637]\]. The underlying etiology of CD is still undetermined \[[@b3-medscimonit-25-9637]\], but it has long been thought as a consequence of an inappropriate mucosal immune response to antigenic stimulation from the gut microbiota in a genetically susceptible host \[[@b4-medscimonit-25-9637]\]. Studies from twins suggested an approximately 50% genetic contribution in CD \[[@b5-medscimonit-25-9637]\]. Therefore, the identification of the related genetic changes that are implicated in CD susceptibility would provide insights into the etiology of this disorder.

To the best of our knowledge, over 200 single nucleotide polymorphisms (SNPs) in several genes (such as *NOD2/CARD15, NOD1/CARD4*, and *ABCB1*) are related to CD in Western populations \[[@b6-medscimonit-25-9637]--[@b9-medscimonit-25-9637]\]. However, due to genetic differences, some SNPs failed to show a link to CD in the Asian population \[[@b10-medscimonit-25-9637],[@b11-medscimonit-25-9637]\]. For example, mutations within genes from the *NOD2/CARD15, ATG16L1*, and *IL23/Th17* signaling pathways were demonstrated to confer susceptibility to CD only in Western patients and not in Chinese and Japanese patients \[[@b12-medscimonit-25-9637]--[@b15-medscimonit-25-9637]\]. In addition, studies in the Asian population have revealed some unique SNPs, e.g., c.374T\>C of the *DLG1* gene in Chinese patients \[[@b16-medscimonit-25-9637]\], *ATG16L2* and/or *FCHSD2* in Chinese and South Korean patients \[[@b17-medscimonit-25-9637],[@b18-medscimonit-25-9637]\], and SNPs in the *TNFSF15* gene in East Asians \[[@b19-medscimonit-25-9637]\]. These differences emphasize the importance of identifying population-specific gene variants.

Perianal fistula CD (pCD) is a subtype of CD with poor prognosis and low quality of life. According to population-based studies, the proportion of pCD ranges from 12% to 40% among CD patients, and this prevalence varies according to disease location and disease duration \[[@b20-medscimonit-25-9637]\]. A European project has revealed that perianal fistula formation in CD patients might be attributed to genes including *IL23R, LOC441108, PRDM1*, and *NOD2* \[[@b21-medscimonit-25-9637]\]. Another study in the Italian population suggested an association of the SNP rs4958847 in the *IRGM* gene with the susceptibility to pCD \[[@b22-medscimonit-25-9637]\]. Studies in Dutch, German, and Norwegian populations found an association between rs2165047 in the *DLG5* gene and the *NOD2* haplotype with perianal development \[[@b23-medscimonit-25-9637],[@b24-medscimonit-25-9637]\]. Furthermore, rs72796353 in *NOD2* was also reported to be significantly associated with perianal fistula development in cases devoid of SNPs rs2066844, rs2066845, and rs2066847 \[[@b25-medscimonit-25-9637]\]. Among the Asian population, only 2 studies have screened potentially pathogenic SNPs in CD patients and explored their associations with perianal fistula formation. One recent study was conducted in a Japanese population and found that the AT haplotype in the *TNFRSF1B* gene might promote fistula development \[[@b26-medscimonit-25-9637]\], while another study in a Korean population revealed the association of the rs4574921 CC genotype within the *TNFSF15* gene with perianal fistula formation \[[@b27-medscimonit-25-9637]\]. However, susceptibility genes and SNPs have never been assessed in the Chinese population. In addition, to reveal the unique gene variants predisposing patients to pCD, it is important to identify the differences in susceptibility genes and SNPs between non-perianal CD (npCD) patients and pCD patients, which have yet to be evaluated.

Here, we extended previous findings in the Asian population by assessing the association between the CD susceptibility *loci* reported in Asians to Southern Chinese CD patients to clarify the specificity of CD susceptibility genes in the Chinese population and further compare the frequencies of those *loci* between pCD and npCD patients to explore the SNPs conferring susceptibility to pCD in the Chinese population.

Material and Methods
====================

Patients
--------

In total, data pertaining to 490 CD patients diagnosed between July 2012 and June 2016 were collected from the Inflammatory Bowel Disease (IBD) Center in the Sixth Affiliated Hospital of Sun Yat-sen University, including 250 patients with perianal fistula and 240 with non-perianal fistula. The CD diagnostic criteria were based on the Expert Consensus Document of IBD diagnosis and treatment in China, 2012 \[[@b28-medscimonit-25-9637]\]. Demographic and clinical information, such as age, sex, race, year of diagnosis, disease location and disease behavior, were collected from all patients. CD behavior includes B1 (non-stricturing, non-penetrating), B2 (stricturing), and B3 (penetrating). In total, 260 healthy volunteers were also recruited from Guangzhou Blood Center.

All included patients and controls were of Han ethnicity and were born in Southern China, including the provinces of Guangdong, Guangxi, Fujian, Jiangxi, Jiangsu, Zhejiang, Hunan, Hubei, Sichuan, Chongqing, Yunnan, Hainan, Taiwan, Hongkong, and Macao.

This study obtained approval from the institutional Review Board of the Sixth Affiliated Hospital, Sun Yat-sen University (IRB number: 2017ZSLYEC-017). Written informed consent was obtained from each participant.

Sample collection
-----------------

Approximately 2 mL of peripheral venous blood was taken from each patient after fasting. The blood sample was centrifuged at 1000 rpm for 10 minutes. After serum removal, the sample was stored at −80°C.

Candidate locus determination
-----------------------------

We searched the MEDLINE, EMBASE and China National Knowledge Infrastructure (CNKI) databases to identify studies reporting the candidate *loci* and genes implicated in Asian CD patients. Finally, 90 *loci* were identified as risk *loci* candidates for screening among CD patients ([Supplementary Table 1](#s1-medscimonit-25-9637){ref-type="supplementary-material"}).

DNA extraction
--------------

DNA was extracted from the peripheral blood leucocytes by standard procedures with a Blood Genomic DNA Isolation Kit (Tiangen, Beijing, China; batch no., DP335). The DNA concentration was determined and then the sample was stored at −20**°**C.

SNP locus sequencing
--------------------

Genotyping was performed with matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) \[[@b29-medscimonit-25-9637]\] on the MassARRAY platform (BGI Tech, Beijing, China).

A 4-μL reaction system consisted of PCR buffer with 1.5 mM MgCl~2~ (0.625 μL), 25 mM MgCl~2~ (0.325 μL), 25 mM dNTPs (0.1 μL), 500 nM Primer Mix (1.0 μL), 5 U/μL HotStar Taq (0.1 μL), and HPLC grade water (1.85 μL). The system was applied to a 384-well plate. Template DNA at 20 ng/μL (1 μL) was added, and a 1-minute centrifugation at 1000 rpm was performed. The amplification conditions included 94**°**C for 5 minutes, followed by 45 cycles of 94**°**C for 20 seconds, 56**°**C for 30 seconds, 72**°**C for 1 minute, and 72**°**C for 3 minutes, with a final holding at 4**°**C.

Shrimp alkaline phosphatase (SAP) mix at 2.0 μL was prepared, which contained 1.53 μL of HPLC grade water, 0.17 μL of SAP buffer (10x), and 0.3 μL of SAP enzyme (1 U/μL). Excess dNTPs were removed from the reaction system by incubating 5 μL of the reaction with the SAP mix at 37**°**C for 20 minutes followed by incubating it at 85**°**C for 5 minutes and then at 4**°**C until used.

Single-based extension liquid was prepared in a final volume of 2 μL, containing 0.2 μL of iPLEX Buffer Plus (0.222×), 0.2 μL of iPLEX Termination Mix (1×), 0.94 μL of Primer Mix (7 μM: 14 μM), and 0.619 μL of HPLC grade water. The liquid was used to produce 9 μL of the single-based extension reaction system. The system was subsequently subjected to 40 cycles of 94**°**C for 30 seconds and 94**°**C for 5 seconds, 5 cycles of 52**°**C for 5 seconds, 45 cycles of 80**°**C for 5 seconds and 72**°**C for 3 minutes, and a final holding step at 4**°**C. Resin purification was performed. After centrifugation, the products were sampled onto a 384-well SpectroChip (Sequenom, USA) for MALDI-TOF MS. The obtained data were analyzed with TYPER4.0.

Statistical analysis
--------------------

All analyses were performed with SPSS version 20.0 (SPSS Inc., Chicago, IL, USA). Comparisons of characteristics among cases with and without perianal fistula and controls were made with one-way analysis of variance (ANOVA) or the chi-squared test whichever applicable; post hoc multiple comparisons were performed by Bonferroni correction analyses. Assessment of the genetic equilibrium of two comparison sets (CD patients versus controls; CD patients with or without perianal fistula) was made using the Hardy-Weinberg equilibrium test. Genotype frequency comparisons between the aforementioned sets were performed with the chi-squared test and are presented as odds ratios (ORs) and 95% confidence intervals (CIs). Haploview 4.2 was utilized for the linkage disequilibrium analysis. All tests were 2-sided, and *P*\<0.05 was considered significant. The genome-wide association study (GWAS) involved statistical comparisons of hundreds of thousands of SNPs. To maintain a significance level of 0.05, the level of inspection for each comparison must be controlled to a certain extent, and we set a significance level for SNP comparisons at *P*\<10^−7^.

Results
=======

Characteristics
---------------

Generally, CD patients were older than the controls. The patients with pCD were older than those with npCD ([Table 1](#t1-medscimonit-25-9637){ref-type="table"}). The majority of cases were male in all 3 groups. In addition, higher percentages of patients with npCD than of those with pCD were single and had penetrating CD.

Risk genetic *loci* screening
-----------------------------

In total, 90 genetic *loci* among 750 patients were identified ([Supplementary Table 1](#s1-medscimonit-25-9637){ref-type="supplementary-material"}). SNPs satisfying a detection rate \>90%, MAF \>5 and Hardy-Weinberg equilibrium were further screened, and 70 were obtained for further analysis ([Supplementary Table 2](#s2-medscimonit-25-9637){ref-type="supplementary-material"}).

Correlation analysis of genotypes in CD patients
------------------------------------------------

### Single SNP association analysis

The frequency comparison between risk *loci* in CD patients and controls ([Supplementary Table 3](#s3-medscimonit-25-9637){ref-type="supplementary-material"}) indicated that 9 SNPs (rs10114470, rs3810936, rs6478109, rs6478108, rs4263839, rs7848647, rs4246905, rs457492, and rs6478106) were significantly related to CD (all with *P*\<10^−7^ in Bonferroni multiplex analysis; [Table 2](#t2-medscimonit-25-9637){ref-type="table"}). Among those SNPs, 5 were C\>T mutations, 2 were G\>A mutations, and the remaining 2 were T\>C mutations. All those variants were located in the *TNFSF15* gene on chromosome 9. Rs6478106 was the only SNP that presented correlation with the pathogenicity of CD (OR=2.15, 95% CI 1.94--3.26), while the remaining SNP exhibited protective roles against CD.

We further assessed the genotype distribution of rs6478106 among different age and gender groups. The results indicated that there were no associations of rs6478106 with age (≤30 *vs*. \>30, χ^2^=0.386, *P*=0.824) or sex (male versus female, χ^2^=2.096, *P*=0.351) ([Table 3](#t3-medscimonit-25-9637){ref-type="table"}).

Haplotype analysis
------------------

Five SNPs (rs4574921, rs6478106, rs10114470, rs3810936, and rs4246905) were found in a 14-kb linkage disequilibrium region (block 1) on chromosome 9, while another 5 SNPs (rs4263839, rs6478108, rs6478109, rs7865494, and rs7848647) were found in a 17-kb linkage disequilibrium region (block 2) on chromosome 9. Haploview analysis showed that the haplotypes CCTTT, TTCCC, CCTCT and TCCTC in block 1 significantly increased the risk of CD (*P*\<0.05).

Correlation analysis between genotype distribution and perianal fistula of CD
-----------------------------------------------------------------------------

### Correlation analysis between single SNP and perianal fistula of CD

The comparison analysis between pCD and npCD patients ([Supplementary Table 4](#s4-medscimonit-25-9637){ref-type="supplementary-material"}) indicated that rs72553867, rs4958847, rs4409764, rs888208, rs3731772, and rs1292053 were candidate SNPs for susceptibility to CD perianal fistula (adjusted *P*\<0.05, according to the Bonferroni test). Rs72553867, rs4958847, rs4409764, rs888208, rs3731772, and rs1292053 are located on chromosomes 5, 5, 10, 2, and 17, respectively. Among these candidates, rs72553867 (OR=1.685, 95% CI 1.188--2.390) and rs4958847 (OR=1.365, 95% CI 1.047--1.778) were found to be located in an *IRGM* coding region on chromosome 5. Rs4409764 (OR=1.329, 95 CI% 1.033--1.709) and rs888208 (OR=1.338, 95% CI 1.032--1.735) were found to be located in the *NKX2--3* gene. Rs3731772 is in the *AOX1* gene (OR=1.335, 95% CI 1.025--1.740), and rs1292053 was in the coding region of *TUBD1* (OR=1.300, 95% CI 1.010--1.674) ([Table 4](#t4-medscimonit-25-9637){ref-type="table"}).

### Adjusted analysis between single SNPs and perianal fistula of CD

We further added age and gender as covariates to the analysis ([Supplementary Table 5](#s5-medscimonit-25-9637){ref-type="supplementary-material"}) and found that rs72553867 located in the *IRGM* gene on chromosome 5 (OR=1.770, 95% CI 1.151--2.723), rs4409764 located in the *NKX2--3* gene on chromosome 10 (OR=1.886, 95% CI 1.181--3.012) and rs3731772 located in the *AOX1* gene on chromosome 2 (OR=2.131, 95% CI 1.150--3.949) were SNPs that conferred susceptibility to pCD.

### Haplotype analysis

Haplotype analysis revealed a 54-kb monomer block in chromosome 5 that contained 4 haplotypes, namely, CTCTAG, TCCCGA, TCACAA, and CTCTAA. Compared with the CTCTAG and CTCTAA haplotypes, haplotypes TCCCGA and TCACAA were associated with pCD (*P*\<0.05).

Discussion
==========

This study showed that 9 SNPs (rs10114470, rs3810936, rs6478109, rs6478108, rs4263839, rs7848647, rs4246905, rs4574921, and rs6478106) located in *TNFSF15* on chromosome 9 are related to CD in the Han population from Southern China. Rs6478106 is the only risk SNP associated with CD. Further analysis revealed that rs72553867 (located in *IRGM* on chromosome 5), rs4409764 (located in *NKX2--3* on chromosome 10) and rs3731772 (located in *AOX1* on chromosome 2) increase the risk of pCD.

*TNFSF15* is mainly expressed in endothelial cells and can be induced in myeloid cells after the ligation of TLR and FcR by IgG ICs and the co-stimulation of T cells through the receptor DR3 \[[@b30-medscimonit-25-9637]\]. Studies have confirmed the upregulated mRNA and protein levels of *TNFSF15* in macrophages and CD4^+^/CD8^+^ lymphocytes in the intestinal lamina propria of CD patients \[[@b31-medscimonit-25-9637]\]. *TNFSF15* can bind to death domain receptor 3 and provide co-stimulatory signals that activate lymphocytes, inducing IFN-γ secretion and prompting participation in inflammatory responses \[[@b32-medscimonit-25-9637],[@b33-medscimonit-25-9637]\]. Therefore, excessive expression of *TNFSF15* can initiate and aggravate mucosal inflammation in CD patients. In European populations, the association of the *TNFSF15* polymorphism with CD susceptibility has been widely reported \[[@b34-medscimonit-25-9637],[@b35-medscimonit-25-9637]\]. Rs4979462 and rs7848647 in *TNFSF15* were reported to be related with CD in Korean and Japanese populations \[[@b18-medscimonit-25-9637],[@b27-medscimonit-25-9637],[@b36-medscimonit-25-9637]\]. In China, only 1 study was conducted on the association between *TNFSF15* and CD, and the authors found that the 3 SNPs in *TNFSF15* (rs3810936, rs6478109, rs7848647) were not significantly associated with CD genetic susceptibility and clinical subtypes in the Han population \[[@b37-medscimonit-25-9637]\], which contrasts with our results that found 9 SNPs (rs10114470, rs3810936, rs6478109, rs6478108, rs4263839, rs7848647, rs4246905, rs4574921, and rs6478106) in *TNFSF15* were related to CD. However, this study had a small sample size (42 CD patients and 49 healthy), which might lead to a limited power to discover significant associations \[[@b37-medscimonit-25-9637]\]. Consistent with the results in the Japanese population \[[@b38-medscimonit-25-9637]\], our analyses also indicated that rs6478106 was a susceptibility SNP for CD. Our analysis further revealed that this association had no relationship with age or sex. Therefore, we propose that the genetic variation of *TNFSF15*, especially rs6478106T, is related to an increased risk for CD in China. The genetic variations of *TNFSF15* in this study may provide evidence regarding the etiology of the disease and information that may be important for the development of treatments.

*IRGM* is widely expressed in various human cells and plays an important regulatory role in intracellular pathogen-associated immunity. IFN-γ can induce the expression of the *IRGM* mouse homologue *LRG-47* and produce auto lysosomes, while the lack of *LRG-47* results in an increased susceptibility to infection \[[@b39-medscimonit-25-9637]\]. The rs13361189 and rs4958847 *loci* of IRGM were confirmed to be related to CD susceptibility in a large-scale clinical trial \[[@b40-medscimonit-25-9637]\]. An Italian study showed that the polymorphisms rs1000113 and rs4958847 in the autophagy gene *IRGM* might participate in the pathogenesis of CD and that the polymorphism of rs4958847 was related to fistula behavior \[[@b22-medscimonit-25-9637]\]. Another study among the Korean population suggested that rs10065172 and rs72553867 are protective factors against the development of CD \[[@b41-medscimonit-25-9637]\]. Although increasing efforts have been devoted to focusing on the associations of *IRGM* mutations with CD, research on CD susceptibility genes in the Han population remains limited. In the study conducted by Zheng et al., 318 CD patients were examined, but no association between the rs13361189 polymorphism in *IRGM* and CD was observed for the Chinese population \[[@b42-medscimonit-25-9637]\], consistent with our result. We also found that in addition to rs4958847, the rs72553867 polymorphism was also closely related to the formation of perianal fistula in the Southern Han population. Our results suggested that *IRGM* gene polymorphisms might affect *IRGM* expression and thus alter the severity of intestinal mucositis.

Previous studies indicated the genetic association of *NKX2--3* with pCD. Yu et al. analyzed the mRNA expression and protein level of *NKX2--3* in American patients with familial IBD and found a significant link of *NKX2--3* to CD \[[@b43-medscimonit-25-9637]\]. Another Japanese study also found that the rs10883365 polymorphism of *NKX2--3* was positively correlated with CD \[[@b44-medscimonit-25-9637]\]. In addition, a Korean study showed that the rs88208 locus in *NKX2--3* was also associated with CD, whereas studies in the Chinese population had the opposite conclusion \[[@b45-medscimonit-25-9637],[@b46-medscimonit-25-9637]\]. In the southern Han population, our study showed a significant relation between the rs4409764 and rs888208 sites of *NKX2--3* and the pathogenesis of pCD. More noteworthy, this study also found that rs3731772 was significantly associated with pCD in the Han population in southern China. The results of our study may provide clues for the function of the *AOX1* gene in patients with fistula CD.

Our study suffered from several potential limitations. First, screening for selected candidate *loci* and genes instead of genome-wide sequencing might lead to missed pathogenic SNPs. However, the selection of our SNP pool was based on multiple related studies that were obtained through a systematic search in MEDLINE and 2 other comprehensive databases in China. Second, we did not perform functional genomics research in this study. Functional analysis is helpful in ascertaining the actual roles of those genes, and our analysis may lay the groundwork for further potential function analyses. Third, although this study is the first confirmative research on susceptibility *loci* associated with perianal fistula CD in the Chinese population, it is preliminary and suffers from a small sample size based on a single center. Thus, the results of this study need to be validated by future multicenter studies with a large sample.

Conclusions
===========

In the Han population from South China, 9 SNPs in *TNFSF15* are related to CD and 3 SNPs located in *IRGM*, *NKX2--3*, and *AOX1* increase the risk of pCD. This study is the first confirmative study on susceptibility *loci* associated with perianal fistula CD in this population, and its results are helpful for the exploration of new disease-associated mechanisms in the future.

Supplementary Data
==================

###### 

Risk locus candidates for screening among CD patients.

  Gene                   SNP           Chr   G-position   Allele   Functional consequence
  ---------------------- ------------- ----- ------------ -------- --------------------------
  *4p14*                 rs1487630     4     38335823     C\>T     Intron variant
  *ATG16L1*              rs2241880     2     234183368    A\>G     Missense
  *ATG16L2*              rs11235604    11    72533536     C\>T     Missense
  *ATG16L2-FCHSD2*       rs11235667    11    72863697     A\>G     
  *BTNL2*                rs28362680    6     32370816     G\>A     Intron variant
  *CARD9*                rs200735402   9     139265120    C\>T     Missense
  *CDKAL1*               rs6908425     6     20728731     T\>C     Intron variant
  *DEFB1*                rs2978880     8     6724306      G\>A     Upstream variant 2KB
  *DNAH12*               rs4462937     3     57414434     A\>G     Missense
  *DR4*                  rs13278062    8     23082971     G\>T     Upstream variant 2KB
  *DR4*                  rs20575       8     23059324     C\>G     Missense
  *DR5*                  rs1047266     8     22900701     G\>A     Intron variant
  *DLG1*                 rs527829647   3     197194534    A\>G     Missense
  *DLG1*                 rs1134986     3     197138371    C\>T     Missense
  *FUT3*                 rs28362459    19    5844781      A\>C     Missense
  *FUT3*                 rs3745635     19    5844332      C\>T     Missense
  *FUT3*                 rs3894326     19    5843773      A\>T     Missense
  *GPR35*                rs3749172     2     241570249    A\>C     Missense
  *HLA-DQA2*             rs3208181     6     32713030     T\>C     Synonymous codon
  *IL-23R*               rs11209026    1     67705958     G\>A     Missense
  *IL-23R*               rs6588248     1     67652984     T\>G     Intron variant
  *IL-23R*               rs7517847     1     67681669     T\>G     Intron variant
  *IL-23R*               rs1004819     1     67670213     G\>A     Intron variant
  *IL-23R*               rs76418789    1     67648596     G\>A     Missense
  *IL-23R*               rs11209032    1     67740092     G\>A     
  *IL-27*                rs153109      16    28507775     T\>C     Intron variant
  *IRF5*                 rs2004640     7     128578301    G\>T     Intron variant
  *IRF5*                 rs3807306     7     128580680    G\>T     Intron variant
  *IRGM*                 rs10065172    5     150848436    C\>T     Synonymous codon
  *IRGM*                 rs11741861    5     150898347    A\>G     Intron variant
  *IRGM*                 rs12654043    5     150846533    A\>G     Utr variant 5 prime
  *IRGM*                 rs13361189    5     150843825    T\>C     
  *IRGM*                 rs4958847     5     150860025    G\>A     Intron variant
  *IRGM*                 rs72553867    5     150848404    C\>A     Missense
  *IRGM*                 rs9637870     5     150848053    G\>A     Utr variant 5 prime
  *IRGM*                 rs9637876     5     150847863    C\>T     Utr variant 5 prime
  *MHC*                  rs7765379     6     32680928     T\>G     
  *MHC*                  rs9271366     6     32619077     G\>A     
  *BTNL2*                rs10947261    6     32405455     G\>T     Intron variant
  *NFKBIA*               rs2273650     14    35870798     C\>T     Utr variant 3 prime
  *NKX2--3*              rs10883365    10    101287764    G\>A     Nc transcript variant
  *NKX2--3*              rs4409764     10    101284237    T\>G     
  *NKX2--3*              rs888208      10    101284237    T\>G     
  *NOTCH4*               rs422951      6     32188383     T\>C     Missense
  *PPP5C*                rs4802307     19    46346549     G\>T     Upstream variant 2KB
  *PTPN2*                rs514000      18    12854073     C\>T     Intron variant
  *PUS10*                rs13003464    2     61186829     A\>G     Intron variant
  *PUS10*                rs7608910     2     60977721     A\>G     Intron variant
  *RNASET2*              rs2149085     6     167371110    T\>C     Upstream variant 2KB
  *SLC22A4*              rs1050152     5     132340627    C\>T     Intron variant
  *SLC25A15-ELF1-WBP4*   rs7329174     13    41558110     A\>G     Intron variant
  *SMNDC1-DUSP5*         rs11195128    10    112186148    C\>T     
  *SOX11*                rs11894081    2     5664008      G\>T     
  *STAT3*                rs1053004     17    40466092     G\>A     Utr variant 3 prime
  *STAT3*                rs9891119     17    40507980     A\>C     Intron variant
  *STAT4*                rs7574865     2     191964633    T\>G     Intron variant
  *TBC1D1-KLF3*          rs6856616     4     38325036     T\>C     
  *TNF-α*                rs1799964     6     31542308     T\>C     Downstream variant 500B
  *TNF-α*                rs1800630     6     31542476     C\>A     Downstream variant 500B
  *TUBD1*                rs1292053     17    59886176     A\>G     Intron variant
  *TNFSF15*              rs10114470    9     117547772    T\>C     Utr variant 3 prime
  *TNFSF15*              rs3810936     9     117552885    T\>C     Synonymous codon
  *TNFSF15*              rs4263839     9     117566440    A\>G     Intron variant
  *TNFSF15*              rs4574921     9     117538334    C\>T     
  *TNFSF15*              rs6478106     9     117545666    C\>T     
  *TNFSF15*              rs6478108     9     117558703    C\>T     Intron variant
  *TNFSF15*              rs6478109     9     117568766    A\>G     Upstream variant 2KB
  *TNFSF15*              rs7848647     9     117569046    T\>C     Upstream variant 2KB
  *TNFSF15*              rs7865494     9     117576479    C\>T     
  *TNFSF15*              rs4246905     9     114790969    T\>C     Intron variant
  *TNFSF8*               rs3181374     9     117665187    A\>G     Intron variant
  *USP25*                rs2823256     21    16784706     G\>A     Intron variant
  *ZMIZ1*                rs1250569     10    81045207     T\>C     Intron variant
  *ZMIZ1*                rs1250546     10    79272775     A\>G     Intron variant
  *ZNF365*               rs224143      10    64477836     G\>A     
                         rs1145816     6     91663151     C\>T     
  *LOC105370520*         rs1495465     14    58016414     C\>A     Upstream variant 2KB
                         rs10761659    10    64445564     A\>G     
  *LOC105379031*         rs7702331     5     73255307     A\>G     Intron variant
                         rs1819333     6     166960059    T\>G     
  *LOC105377139*         rs7282490     21    44195858     G\>A     Upstream variant 2KB
  *NDUT15*               rs186364861   13    48611934     G\>A     Missense
  *ABCC4*                rs3765534     13    95815415     C\>T     Missense
  *AOX1*                 rs3731772     2     12739259     T\>C     
  *ITPA*                 rs1127354     20    3193842      C\>A     Intron variant, missense
  *MTHFR*                rs1801133     1     11856378     G\>A     Missense
  *GSTP1*                rs1695        11    67585218     A\>G     Missense
  *RANTES/CCL5*          rs2107538     17    34207780     C\>T     Intron variant
  *CCR5*                 rs1799987     3     46411935     A\>G     Intron variant
  *CCR5*                 rs3181036     3     46412559     C\>T     Intron variant

###### 

SNPs selected for analysis.

  No.   SNP          No.   SNP          No.   SNP          No.   SNP
  ----- ------------ ----- ------------ ----- ------------ ----- ------------
  1     rs1004819    19    rs3765534    37    rs6478108    55    rs1801133
  2     rs10065172   20    rs3810936    38    rs7608910    56    rs10883365
  3     rs10114470   21    rs514000     39    rs2107538    57    rs1127354
  4     rs1053004    22    rs6478109    40    rs3181374    58    rs1250546
  5     rs10761659   23    rs2149085    41    rs3894326    59    rs1819333
  6     rs11195128   24    rs3749172    42    rs4462937    60    rs2823256
  7     rs11741861   25    rs422951     43    rs4958847    61    rs3731772
  8     rs13361189   26    rs7282490    44    rs6478106    62    rs4246905
  9     rs1799964    27    rs7574865    45    rs7517847    63    rs4574921
  10    rs2004640    28    rs888208     46    rs7848647    64    rs72553867
  11    rs2241880    29    rs11209032   47    rs7865494    65    rs7702331
  12    rs3208181    30    rs11235667   48    rs11235604   66    rs1487630
  13    rs3807306    31    rs1292053    49    rs1250569    67    rs1695
  14    rs4409764    32    rs1799987    50    rs153109     68    rs1800630
  15    rs2273650    33    rs4263839    51    rs3181036    69    rs1047266
  16    rs3745635    34    rs6588248    52    rs11894081   70    rs10947261
  17    rs7329174    35    rs6908425    53    rs13003464         
  18    rs7765379    36    rs9637876    54    rs1134986          

###### 

Analysis results for 70 SNPs related to CD.

  SNP          Chr.   Gene               Frequency among the CD group   Frequency among controls   Allelic test P-value   OR       95% CI
  ------------ ------ ------------------ ------------------------------ -------------------------- ---------------------- -------- ------------------
  rs10114470   9      *TNFSF15*          0.3834                         0.5656                     1.41E-11               0.4774   (0.3847, 0.5925)
  rs3810936    9      *TNFSF15*          0.3826                         0.565                      2.40E-11               0.4772   (0.3835, 0.5938)
  rs6478109    9      *TNFSF15*          0.3702                         0.5386                     3.55E-10               0.5035   (0.4058, 0.6247)
  rs6478108    9      *TNFSF15*          0.374                          0.5425                     3.71E-10               0.5039   (0.4061, 0.6252)
  rs4263839    9      *TNFSF15*          0.3729                         0.5405                     5.08E-10               0.5055   (0.4072, 0.6277)
  rs7848647    9      *TNFSF15*          0.3714                         0.5388                     5.11E-10               0.5059   (0.4075, 0.628)
  rs4246905    9      *TNFSF15*          0.2645                         0.4189                     1.18E-09               0.4989   (0.3981, 0.6252)
  rs4574921    9      *TNFSF15*          0.2656                         0.4189                     1.55E-09               0.5015   (0.4003, 0.6285)
  rs6478106    9      *TNFSF15*          0.3249                         0.1827                     4.29E-09               2.153    (1.661, 2.79)
  rs11209032   1      *IL-23R*           0.4451                         0.5598                     2.35E-05               0.6307   (0.5091, 0.7814)
  rs6588248    1      *IL23R*            0.3119                         0.4066                     0.0002632              0.6613   (0.5293, 0.8263)
  rs7329174    13     *ELF1*             0.2758                         0.1988                     0.001074               1.535    (1.186, 1.986)
  rs422951     6      *NOTCH4*           0.146                          0.2115                     0.00125                0.6374   (0.4843, 0.8391)
  rs7517847    1      *IL23R*            0.3831                         0.4692                     0.001257               0.7025   (0.5667, 0.871)
  rs13361189   5      *IRGM*             0.5031                         0.4205                     0.0024                 1.395    (1.125, 1.73)
  rs10065172   5      *IRGM*             0.5                            0.4186                     0.002739               1.389    (1.12, 1.722)
  rs11235604   11     *ATG16L2*          0.1374                         0.08687                    0.004163               1.674    (1.173, 2.388)
  rs888208     10     *NKX2--3*          0.3776                         0.4537                     0.004294               0.7304   (0.5886, 0.9064)
  rs1487630    4      *4p14*             0.2789                         0.2115                     0.004379               1.442    (1.12, 1.855)
  rs4958847    5      *IRGM*             0.3459                         0.4187                     0.006374               0.7342   (0.5879, 0.917)
  rs9637876    5      *IRGM*             0.4918                         0.4189                     0.007165               1.342    (1.083, 1.664)
  rs11235667   11     *ATG16L2-FCHSD2*   0.1381                         0.09073                    0.007553               1.606    (1.132, 2.278)
  rs11741861   5      *ZNF300*           0.4706                         0.4                        0.00879                1.333    (1.075, 1.654)
  rs1004819    1      *IL23R*            0.3842                         0.4514                     0.01217                0.7584   (0.6109, 0.9416)
  rs10883365   10     *LINC01475*        0.5228                         0.4554                     0.01347                1.31     (1.057, 1.623)
  rs3745635    19     *FUT3*             0.1701                         0.1236                     0.01765                1.454    (1.066, 1.982)
  rs1799987    3      *CCR5*             0.3499                         0.4115                     0.01857                0.7696   (0.6187, 0.9573)
  rs11195128   10     *SMNDC1-DUSP5*     0.1724                         0.1269                     0.02095                1.433    (1.055, 1.947)
  rs514000     18     *PTPN2*            0.4168                         0.3546                     0.02101                1.301    (1.04, 1.627)
  rs4409764    10     *NKX2--3*          0.4765                         0.5388                     0.02207                0.7792   (0.6292, 0.9649)
  rs10947261   6      *BTNL2*            0.335                          0.281                      0.03279                1.289    (1.021, 1.628)
  rs3749172    2      *GPR35*            0.3641                         0.3105                     0.04015                1.271    (1.011, 1.599)
  rs153109     16     *IL27*             0.4074                         0.3533                     0.04123                1.259    (1.009, 1.57)
  rs7765379    6      *MHC*              0.1068                         0.07529                    0.04907                1.469    (0.9997, 2.159)
  rs3181374    10     *TNFSF8*           0.425                          0.4764                     0.06347                0.8124   (0.6523, 1.012)
  rs3181036    3      *CCR5*             0.168                          0.2066                     0.0651                 0.7757   (0.592, 1.016)
  rs1053004    17     *STAT3*            0.3476                         0.3923                     0.08707                0.8255   (0.6626, 1.028)
  rs6908425    6      *CDKAL1*           0.1476                         0.1815                     0.0897                 0.7811   (0.587, 1.039)
  rs7865494    9      *TNFSF15*          0.2879                         0.249                      0.109                  1.219    (0.9566, 1.554)
  rs7574865    2      *STAT4*            0.3398                         0.3813                     0.1108                 0.835    (0.669, 1.042)
  rs13003464   2      *PUS10*            0.05215                        0.03475                    0.1269                 1.528    (0.8833, 2.644)
  rs2004640    7      *IRF5*             0.2945                         0.2577                     0.1319                 1.202    (0.9459, 1.528)
  rs7282490    21     *LOC105377139*     0.449                          0.4884                     0.1463                 0.8536   (0.6894, 1.057)
  rs1250546    10     *ZMIZ1*            0.4213                         0.4593                     0.16                   0.8571   (0.6912, 1.063)
  rs1292053    17     *TUBD1*            0.4483                         0.4826                     0.2055                 0.8712   (0.7038, 1.079)
  rs10761659   10     *LOC105370520*     0.2162                         0.2442                     0.2187                 0.8537   (0.6635, 1.099)
  rs7608910    2      *PUS10*            0.05263                        0.03846                    0.22                   1.389    (0.82, 2.353)
  rs2273650    14     *NFKBIA*           0.2684                         0.2934                     0.3062                 0.8835   (0.6968, 1.12)
  rs11894081   2      *SOX11*            0.4214                         0.3944                     0.3205                 1.118    (0.897, 1.394)
  rs1250569    10     *ZMIZ1*            0.4287                         0.4535                     0.3584                 0.9044   (0.7298, 1.121)
  rs2823256    21     *LOC101927745*     0.3126                         0.3359                     0.3598                 0.8992   (0.7162, 1.129)
  rs2241880    2      *ATG16L1*          0.3742                         0.3514                     0.3813                 1.104    (0.8845, 1.378)
  rs3807306    7      *IRF5*             0.1829                         0.166                      0.4147                 1.125    (0.848, 1.491)
  rs72553867   5      *IRGM*             0.1596                         0.1757                     0.4237                 0.8908   (0.671, 1.183)
  rs7702331    5      *LOC105379031*     0.1154                         0.1293                     0.431                  0.878    (0.635, 1.214)
  rs1134986    3      *DLG1*             0.06302                        0.05405                    0.4878                 1.177    (0.7425, 1.866)
  rs1801133    1      *MTHFR*            0.2957                         0.2791                     0.5012                 1.085    (0.8561, 1.374)
  rs3894326    19     *FUT3*             0.1447                         0.1564                     0.5467                 0.913    (0.6791, 1.228)
  rs2107538    17     *CCL5*             0.3418                         0.3295                     0.6314                 1.057    (0.8432, 1.325)
  rs1799964    6      *LTA*              0.1752                         0.1846                     0.6486                 0.9379   (0.7117, 1.236)
  rs1800630    6      *LTA*              0.1586                         0.1673                     0.6617                 0.938    (0.7043, 1.249)
  rs2149085    6      *RNASET2*          0.3929                         0.3833                     0.7181                 1.041    (0.8362, 1.296)
  rs1047266    8      *TNFRSF10B*        0.277                          0.2857                     0.7208                 0.9577   (0.7555, 1.214)
  rs3731772    2      *AOX1*             0.3508                         0.3417                     0.7247                 1.041    (0.8319, 1.303)
  rs4462937    3      *DNAH12*           0.3931                         0.4023                     0.7281                 0.962    (0.7735, 1.197)
  rs1819333    6      *LOC105379031*     0.3909                         0.3822                     0.7426                 1.037    (0.8333, 1.292)
  rs1127354    20     *ITPA*             0.1711                         0.1647                     0.7537                 1.047    (0.7862, 1.394)
  rs3208181    6      *HLA-DQA2*         0.1245                         0.1192                     0.7671                 1.05     (0.7585, 1.455)
  rs1695       11     *GSTP1*            0.1765                         0.1712                     0.7941                 1.038    (0.7837, 1.375)
  rs3765534    13     *ABCC4*            0.05183                        0.05385                    0.8676                 0.9605   (0.5981, 1.543)

SNPs are ordered according to *P* values. Chr -- chromosome.

###### 

Analysis results for SNPs related to pCD.

  Name         Chr. No.   Gene or locus      Major/minor allele   Risk allele   Case RAF   Control RAF   OR (95% CI)            *P* value allele   *P* value genotype
  ------------ ---------- ------------------ -------------------- ------------- ---------- ------------- ---------------------- ------------------ ----------------------------------------------------------
  rs72553867   chr5       *IRGM*             C/A                  A             0.194      0.125         1.685 (1.188--2.390)   0.003              0.002[a](#tfn5-medscimonit-25-9637){ref-type="table-fn"}
  rs4958847    chr5       *IRGM*             A/G                  A             0.688      0.617         1.365 (1.047--1.778)   0.021              0.025[c](#tfn7-medscimonit-25-9637){ref-type="table-fn"}
  rs4409764    chr10      *NKX2--3*          G/T                  T             0.558      0.487         1.329 (1.033--1.709)   0.027              0.007[a](#tfn5-medscimonit-25-9637){ref-type="table-fn"}
  rs888208     chr10      *NKX2--3*          A/G                  A             0.656      0.588         1.338 (1.032--1.735)   0.028              0.004[a](#tfn5-medscimonit-25-9637){ref-type="table-fn"}
  rs3731772    chr2       *AOX1*             T/C                  T             0.681      0.615         1.335 (1.025--1.740)   0.032              0.032[a](#tfn5-medscimonit-25-9637){ref-type="table-fn"}
  rs1292053    chr17      *TUBD1*            G/A                  A             0.482      0.417         1.300 (1.010--1.674)   0.041              0.035[c](#tfn7-medscimonit-25-9637){ref-type="table-fn"}
  rs3894326    chr19      *FUT3*             A/T                  A             0.880      0.836         1.438 (1.001--2.064)   0.049              0.045[c](#tfn7-medscimonit-25-9637){ref-type="table-fn"}
  rs10883365   chr10      *NKX2--3*          A/G                  G             0.548      0.496         1.234 (0.957--1.590)   0.105              0.033[a](#tfn5-medscimonit-25-9637){ref-type="table-fn"}
  rs3181374    chr9       *TNFSF8*           A/G                  A             0.687      0.642         1.226 (0.939--1.600)   0.135              0.069[a](#tfn5-medscimonit-25-9637){ref-type="table-fn"}
  rs11235667   chr11      *ATG16L2-FCHSD2*   A/G                  A             0.877      0.844         1.314 (0.914--1.887)   0.139              0.148[c](#tfn7-medscimonit-25-9637){ref-type="table-fn"}
  rs3749172    chr2       *GPR35*            C/A                  A             0.387      0.343         1.209 (0.926--1.577)   0.162              0.055[b](#tfn6-medscimonit-25-9637){ref-type="table-fn"}
  rs2241880    chr2       *ATG16L1*          A/G                  G             0.394      0.355         1.185 (0.915--1.534)   0.199              0.182[b](#tfn6-medscimonit-25-9637){ref-type="table-fn"}
  rs153109     chr16      *IL27*             T/C                  T             0.613      0.573         1.181 (0.914--1.526)   0.204              0.094[a](#tfn5-medscimonit-25-9637){ref-type="table-fn"}
  rs1800630    chr6       *TNF*              C/A                  C             0.857      0.828         1.242 (0.881--1.752)   0.216              0.168[b](#tfn6-medscimonit-25-9637){ref-type="table-fn"}
  rs11235604   chr11      *ATG16L2*          C/T                  C             0.875      0.848         1.256 (0.873--1.805)   0.219              0.225[c](#tfn7-medscimonit-25-9637){ref-type="table-fn"}
  rs7282490    chr21      *ICOSLG*           G/A                  A             0.468      0.429         1.168 (0.907--1.504)   0.228              0.205[b](#tfn6-medscimonit-25-9637){ref-type="table-fn"}
  rs2107538    chr17      *CCL5*             C/T                  T             0.360      0.325         1.168 (0.897--1.522)   0.249              0.239[c](#tfn7-medscimonit-25-9637){ref-type="table-fn"}
  rs10114470   chr9       *TNFSF15*          C/T                  C             0.633      0.598         1.160 (0.897--1.500)   0.259              0.128[a](#tfn5-medscimonit-25-9637){ref-type="table-fn"}
  rs514000     chr18      *PTPN2*            T/C                  T             0.600      0.564         1.160 (0.895--1.501)   0.262              0.106[a](#tfn5-medscimonit-25-9637){ref-type="table-fn"}
  rs11209032   chr1       *IL23R-IL12RB2*    A/G                  G             0.464      0.429         1.149 (0.893--1.478)   0.281              0.275[a](#tfn5-medscimonit-25-9637){ref-type="table-fn"}

SNPs are ordered according to *P* values.

p value for the dominant model;

p value for the regressive model;

p value for the additive model.

Chr -- chromosome; RAF -- risk allele frequency

###### 

Logistic analysis results for SNPs related to pCD.

                                                                  Risk allele       Univariate             Multivariate                          
  --------------------------------------------------------------- ----------------- ---------------------- -------------- ---------------------- ---------
  rs72553867[a](#tfn9-medscimonit-25-9637){ref-type="table-fn"}   AC+AA *vs*. CC    1.874 (1.246--2.817)   0.003          1.770 (1.151--2.723)   0.009
  rs4958847[c](#tfn10-medscimonit-25-9637){ref-type="table-fn"}   A *vs*. G         1.366 (1.045--1.786)   0.023          --                     --
  rs4409764[a](#tfn9-medscimonit-25-9637){ref-type="table-fn"}    GT+TT *vs*. GG    1.780 (1.149--2.758)   0.010          1.886 (1.181--3.012)   0.008
  rs888208[a](#tfn9-medscimonit-25-9637){ref-type="table-fn"}     AG+AA *vs*. GG    2.087 (1.205--3.616)   0.009          --                     --
  rs3731772[a](#tfn9-medscimonit-25-9637){ref-type="table-fn"}    T C+TT *vs*. CC   1.941 (1.099--3.428)   0.022          2.131 (1.150--3.949)   0.016
  rs1292053[a](#tfn9-medscimonit-25-9637){ref-type="table-fn"}    AG+AA *vs*. GG    1.487 (0.992--2.230)   0.055          --                     --
  rs3894326[c](#tfn10-medscimonit-25-9637){ref-type="table-fn"}   A *vs*. T         1.380 (0.943--2.017)   0.097          --                     --
  Age (year)                                                                        /                      /              0.968 (0.951--0.984)   \<0.001
  Male/Female                                                                       /                      /              1.608 (1.059--2.442)   0.026

Dominant model;

additive model.
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###### 

Clinical characteristics of CD patients and healthy controls.

  Characteristics      CD with perianal fistula (n=250)   CD without perianal fistula (n=240)   Controls (n=260)   F/χ^2^ value   *P* value
  -------------------- ---------------------------------- ------------------------------------- ------------------ -------------- -----------
  Age (years)          32.61±13.32                        28.51±9.72                            24.34±3.96         52.66          \<0.001
  Male (n, %)          156 (62.4)                         186 (77.5)                            174 (66.9)         12.931         0.002
  Location (n, %)                                                                                                  2.72           0.26
   Ileal±upper         17 (6.8)                           26 (10.8)                             NA                                
   Colonic±upper       26 (10.4)                          27 (11.3)                             NA                                
   Ileocolonic±upper   207 (82.8)                         187 (77.9)                            NA                                
  Behavior (n, %)                                                                                                  58.956         \<0.001
   B1                  63 (25.2)                          35 (14.6)                             NA                                
   B2                  72 (28.8)                          39 (16.3)                             NA                                
   B3                  115 (46.0)                         176 (73.3)                            NA                                

CD -- Crohn's disease; B1 -- non-stricturing, non-penetrating; B2 -- structuring; B3 -- penetrating; NA -- not applicable.

###### 

CD-related SNPs.

  Chromosome no.   dbSNP        Gene        Major allele   Risk allele   Frequency among CD group   Frequency among controls   Allelic test *P*-value   OR      95% CI
  ---------------- ------------ ----------- -------------- ------------- -------------------------- -------------------------- ------------------------ ------- ----------------
  9                rs10114470   *TNFSF15*   C              T             0.283                      0.566                      1.41E-11                 0.477   (0.385, 0.593)
  9                rs3810936    *TNFSF15*   C              T             0.383                      0.565                      2.40E-11                 0.477   (0.384, 0.594)
  9                rs6478109    *TNFSF15*   G              A             0.370                      0.539                      3.55E-10                 0.504   (0.406, 0.625)
  9                rs6478108    *TNFSF15*   T              C             0.274                      0.543                      3.71E-10                 0.504   (0.406, 0.625)
  9                rs4263839    *TNFSF15*   G              A             0.373                      0.541                      5.08E-10                 0.506   (0.407, 0.628)
  9                rs7848647    *TNFSF15*   C              T             0.371                      0.539                      5.11E-10                 0.506   (0.408, 0.628)
  9                rs4246905    *TNFSF15*   C              T             0.265                      0.429                      1.18E-09                 0.499   (0.398, 0.625)
  9                rs457492     *TNFSF15*   T              C             0.266                      0.419                      1.55E-09                 0.502   (0.400, 0.628)
  9                rs6478106    *TNFSF15*   C              T             0.325                      0.183                      4.29E-09                 2.153   (1.939, 3.257)

###### 

Distribution of rs6478106 genotypes in different ages and sexes.

                Genotypes (n)   χ^2^   *P* value                
  ------------- --------------- ------ ----------- ---- ------- -------
  Age (years)   ≤30             112    106         24   0.386   0.824
  \>30          108             115    25                       
  Sex           Male            77     64          14   2.096   0.351
  Female        143             157    35                       

###### 

Perianal fistula of CD-associated SNP *loci*.

  Name         Chr. no   Gene or locus   Major/minor allele   Risk allele   pCD group RAF   CD group RAF   OR (95% CI)            *P* allele
  ------------ --------- --------------- -------------------- ------------- --------------- -------------- ---------------------- ------------
  rs72553867   chr5      *IRGM*          C/A                  A             0.194           0.125          1.685 (1.188--2.390)   0.003
  rs4958847    chr5      *IRGM*          A/G                  A             0.688           0.617          1.365 (1.047--1.778)   0.021
  rs4409764    chr10     *NKX2--3*       G/T                  T             0.558           0.487          1.329 (1.033--1.709)   0.027
  rs888208     chr10     *NKX2--3*       A/G                  A             0.656           0.588          1.338 (1.032--1.735)   0.028
  rs3731772    chr2      *AOX1*          T/C                  T             0.681           0.615          1.335 (1.025--1.740)   0.032
  rs1292053    chr17     *TUBD1*         G/A                  A             0.482           0.417          1.300 (1.010--1.674)   0.041

Chr. -- chromosome; RAF -- risk allele frequency.
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